Singulair en es it fr

Singulair Brand names, Singulair Analogs

Singulair Brand Names Mixture

  • No information avaliable

Singulair Chemical_Formula


Singulair RX_link

Singulair fda sheet

Singulair FDA

Singulair msds (material safety sheet)

Singulair Synthesis Reference

M. L. Belley et al., Eur. Pat. Appl. 480,717 (1992)

Singulair Molecular Weight

586.184 g/mol

Singulair Melting Point

No information avaliable

Singulair H2O Solubility

No information avaliable

Singulair State


Singulair LogP


Singulair Dosage Forms

Tablet (oral)

Singulair Indication

For the treatment of asthma

Singulair Pharmacology

Montelukast, like zafirlukast, is a leukotriene receptor antagonist used as an alternative to anti-inflammatory medications in the management and chronic treatment of asthma and exercise-induced bronchospasm (EIB). Unlike zafirlukast, montelukast does not inhibit CYP2C9 or CYP3A4 and is, therefore, not expected to affect the hepatic clearance of drugs metabolized by these enzymes.

Singulair Absorption

Rapidly absorbed following oral administration (bioavailability is 64%)

Singulair side effects and Toxicity

Side effects include headache, abdominal or stomach pain, cough, dental pain, dizziness, fever, heartburn, skin rash, stuffy nose, weakness or unusual tiredness.

Singulair Patient Information


  • Patients should be advised to take montelukast daily as prescribed, even when they are asymptomatic, as well as during periods of worsening asthma, and to contact their physicians if their asthma is not well controlled.
  • Patients should be advised that oral tablets of montelukast are not for the treatment of acute asthma attacks. They should have appropriate short-acting inhaled b-agonist medication available to treat asthma exacerbations.
  • Patients should be advised that, while using montelukast, medical attention should be sought if short-acting inhaled bronchodilators are needed more often than usual, or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for 24-hour period are needed.
  • Patients receiving montelukast should be instructed not to decrease the dose or stop taking any other antiasthma medications unless instructed by a physician.
  • Patients who have exacerbations of asthma after exercise should be instructed to continue to use their usual regimen of inhaled b-agonists as prophylaxis unless otherwise instructed by their physician. All patients should have available for rescue a short-acting inhaled b-agonist.
  • Patients with known aspirin sensitivity should be advised to continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking montelukast.
Chewable Tablets:

Phenylketonurics: Phenylketonuric patients should be informed that the chewable tablet contains phenylalanine (a component of aspartame) 0.842 mg per 5-mg chewable tablet.

Singulair Organisms Affected

Humans and other mammals